Abstract
IntroductionRadiolabelled prostate-specific membrane antigen PSMA-based PET/CT or PET/MRI is a whole-body imaging technique usually performed for the detection of prostate cancer lesions. PSMA has been also demonstrated to be expressed by the neovasculature of many other solid tumors. The aim of this review is to evaluate the possible diagnostic role of radiolabelled PSMA PET/CT or PET/MRI in patients with hepatocellular carcinoma, by summarizing the available literature data.MethodsA wide literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane library databases was made to find relevant published articles about the diagnostic performance of radiolabelled PSMA binding agents in PET/CT or PET/MRI imaging of patients with hepatocellular carcinoma.ResultsTen case reports and three studies showed that hepatocellular carcinoma is PSMA-avid.ConclusionRadiolabelled PSMA imaging seems to be useful in analyzing hepatocellular carcinoma. Further studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of radiolabelled PSMA in this setting.
Highlights
Radiolabelled prostate-specific membrane antigen PSMA-based positron emission tomography (PET)/CT or PET/MRI is a whole-body imaging technique usually performed for the detection of prostate cancer lesions
Radiolabelled Gallium-68 (68Ga) or Fluorine-18 (18F) prostate-specific membrane antigen (PSMA)-based positron emission tomography/ computed tomography or magnetic resonance imaging (PET/ CT or PET/MRI) are imaging techniques normally used for the evaluation and the diagnosis of prostate cancer (PCa) lesions
The aim of this review is to evaluate the possible diagnostic role of radiolabelled PSMA PET/CT or PET/MRI in patients with Hepatocellular carcinoma (HCC) by summarizing the available literature data
Summary
Radiolabelled prostate-specific membrane antigen PSMA-based PET/CT or PET/MRI is a whole-body imaging technique usually performed for the detection of prostate cancer lesions. The aim of this review is to evaluate the possible diagnostic role of radiolabelled PSMA PET/CT or PET/MRI in patients with hepatocellular carcinoma, by summarizing the available literature data. Radiolabelled Gallium-68 (68Ga) or Fluorine-18 (18F) prostate-specific membrane antigen (PSMA)-based positron emission tomography/ computed tomography or magnetic resonance imaging (PET/ CT or PET/MRI) are imaging techniques normally used for the evaluation and the diagnosis of prostate cancer (PCa) lesions. PSMA-based imaging is usually performed for the initial staging of intermediate to high risk PCa; restaging after biochemical disease relapse (rising prostate-specific antigen levels) in patients with prior radical prostatectomy or radical external beam radiation are important field of application [6–8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
